Modular Microphysiological System for Leukemia Drug Testing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer research lacks robust preclinical models to accurately predict the efficacy and safety of new drugs, particularly for leukemia, due to limitations in existing tumor models that fail to recapitulate human pathophysiology and tumor progression, leading to ineffective drug development and high false positives in clinical trials.
Innovation Solution
A modular microphysiological system with vascular perfusion that integrates bioengineered human tumors with target tissues, allowing for systemic tissue communication and maintaining tissue-specific phenotypes, enabling more accurate drug testing and toxicity prediction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional 2D cell culture models are used, then the system is simple and easy to maintain, but the model fails to recapitulate human pathophysiology and tumor progression
Solution Approach 1:
The patent implements a nested structure where tumor organoids are embedded within a hydrogel matrix, which is then encapsulated in a microfluidic device. This nested arrangement allows complex physiological functions to be contained within a manageable system architecture, improving predictive accuracy while controlling complexity through hierarchical organization.
Solution Approach 2:
The patent transitions from traditional 2D monolayer cultures to 3D tumor organoids with vascular networks. This dimensional change enables more realistic tumor architecture, cell-cell interactions, and drug penetration patterns, significantly improving the reliability of preclinical drug testing.
2Reliability
If animal models are used to study tumor progression, then a more physiological environment is provided, but the models are laborious, expensive, and do not support fine-grain control of exogenous factors
Solution Approach 1:
The patent employs microfluidic hydraulic systems to deliver precise control over nutrient flow, drug administration, and waste removal. This hydraulic control mechanism provides fine-grain control of exogenous factors while maintaining physiological relevance through realistic flow dynamics and tissue perfusion patterns.
Solution Approach 2:
The patent introduces a hydrogel matrix as an intermediary between the tumor organoids and the external environment. This hydrogel mediator provides structural support, mimics the extracellular matrix, and allows controlled diffusion of nutrients and drugs, bridging the gap between in vitro simplicity and in vivo physiological complexity.
3Reliability
If existing tumor models are used, then the modeling is simpler, but they fail to recapitulate critical aspects of human pathophysiology such as tumor-stroma interactions and metastatic progression
Solution Approach 1:
The patent segments the tumor microenvironment into distinct functional compartments including tumor organoids, stromal cells, immune cells, and vascular networks. Each segment can be independently cultured and optimized, then integrated to create a comprehensive model that recapitulates human pathophysiology while managing complexity through modular design.
Solution Approach 2:
The patent creates a composite tissue model combining multiple cell types (tumor cells, stromal cells, endothelial cells) within a hydrogel matrix. This composite structure mimics the complexity of human tumor microenvironments, enabling realistic study of tumor-stroma interactions and metastatic progression.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The system provides a highly advanced 'cancer patient on a chip' model that recapitulates multi-organ drug toxicities and biomarkers, facilitating clinical translation and reliable drug development by maintaining tissue health and functionality while allowing for systemic communication and drug testing.
Implementation Method 1
a vascular network comprising at least one channel, wherein each of said endothelial barriers in in fluid contact with at least one of said at least one channel; and circulating a culture medium through the vascular network
Data Source
AI summary
A modular bioreactor system is provided including a platform having a seat to receive a modular tissue chamber, and one or more platform interfacial members; and a releasable modular tissue chamber including a bottom surface, an open top, and sidewalls defining a well therein, the releasable modular tissue chamber configured to be received by the seat of the platform, the tissue chamber further including an interfacial member configured to releasably connect the modular tissue chamber to the platform, wherein a tissue chamber contains human bone marrow (engineered using iPS cell derived osteoblasts, osteoclasts, endothelial cells, supporting mesenchymal cells, and hematopoietic cells in bone matrix) infused by primary leukemia cells